Abstract
Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Current Pharmacogenomics and Personalized Medicine
Title:Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Volume: 10 Issue: 4
Author(s): Y. W. Francis Lam
Affiliation:
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Abstract: Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Export Options
About this article
Cite this article as:
Lam W. Francis Y., Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem, Current Pharmacogenomics and Personalized Medicine 2012; 10(4) . https://dx.doi.org/10.2174/187569212803901828
DOI https://dx.doi.org/10.2174/187569212803901828 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Radiolabeled Peptides for SPECT and PET Imaging in the Detection of Breast Cancer: Preclinical and Clinical Perspectives
Current Medicinal Chemistry Quantitative Structure – Activity Relationship Study on Saponins as Cytotoxicity Enhancers
Letters in Drug Design & Discovery Phytochemicals - A Novel and Prominent Source of Anti-cancer Drugs Against Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Functionalized Magnetic Nanostructures for Anticancer Therapy
Current Drug Targets Anti-adipogenic and Cytotoxic Effects of a New Compound from <i>Hartmannia rosea</i> G. Don
Current Pharmaceutical Analysis Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology General Aspects of Metal Toxicity
Current Medicinal Chemistry Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design D Allele Frequency in Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme (ACE) Gene is Associated with Development of Breast Cancer Risk in Indian Women
Current Proteomics Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Current Topics in Medicinal Chemistry Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery